{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,21]],"date-time":"2026-10-21T10:24:04Z","timestamp":1792578244186,"version":"4.5.0"},"reference-count":23,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2014,4,1]],"date-time":"2014-04-01T00:00:00Z","timestamp":1396310400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Annals of Epidemiology"],"published-print":{"date-parts":[[2014,4]]},"DOI":"10.1016\/j.annepidem.2013.12.009","type":"journal-article","created":{"date-parts":[[2014,1,2]],"date-time":"2014-01-02T17:45:52Z","timestamp":1388684752000},"page":"279-285","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":63,"title":["Peripheral neuropathy and Guillain-Barr\u00e9 syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis"],"prefix":"10.1016","volume":"24","author":[{"given":"Ayad K.","family":"Ali","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.annepidem.2013.12.009_bib1","unstructured":"Food and Drug Administration. Ciprofloxacin label revision letter. 14 July 2004. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo [accessed 29 August 2013]."},{"key":"10.1016\/j.annepidem.2013.12.009_bib2","unstructured":"Food and Drug Administration. Levofloxacin label revision letter. 14 September 2004. http:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/appletter\/2004\/20634s033,034,20635s033,034ltr.pdf [accessed 29 August 2013]."},{"key":"10.1016\/j.annepidem.2013.12.009_bib3","unstructured":"Food and Drug Administration. Moxifloxacin label revision letter. 28 July 2004. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo [accessed 29 August 2013]."},{"key":"10.1016\/j.annepidem.2013.12.009_bib4","unstructured":"Food and Drug Administration. Norfloxacin label revision letter. 23 July 2004. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo [accessed 29 August 2013]."},{"key":"10.1016\/j.annepidem.2013.12.009_bib5","unstructured":"Food and Drug Administration. Ofloxacin label revision letter. 15 September 2004. http:\/\/www.accessdata.fda.gov\/scripts\/cder\/drugsatfda\/index.cfm?fuseaction=Search.Label_ApprovalHistory#labelinfo [accessed 29 August 2013]."},{"key":"10.1016\/j.annepidem.2013.12.009_bib6","unstructured":"Food and Drug Administration. FDA Drug Safety Communication: FDA requires label changes to warn of risk for possibly permanent nerve damage from antibacterial fluoroquinolone drugs taken by mouth or by injection. 15 August 2013. http:\/\/www.fda.gov\/downloads\/Drugs\/DrugSafety\/UCM365078.%20pdf [accessed 15 August 2013]."},{"issue":"1","key":"10.1016\/j.annepidem.2013.12.009_bib7","doi-asserted-by":"crossref","first-page":"39","DOI":"10.1212\/WNL.0b013e3181aaea47","article-title":"Incidence and prevalence of CIDP and the association of diabetes mellitus","volume":"73","author":"Laughlin","year":"2009","journal-title":"Neurology"},{"issue":"7","key":"10.1016\/j.annepidem.2013.12.009_bib8","first-page":"887","article-title":"Peripheral neuropathy: differential diagnosis and management","volume":"81","author":"Azhary","year":"2010","journal-title":"Am Fam Physician"},{"issue":"9","key":"10.1016\/j.annepidem.2013.12.009_bib9","doi-asserted-by":"crossref","first-page":"873","DOI":"10.1093\/aje\/kwj281","article-title":"Peripheral insensate neuropathy\u2014a tall problem for US adults?","volume":"164","author":"Cheng","year":"2006","journal-title":"Am J Epidemiol"},{"key":"10.1016\/j.annepidem.2013.12.009_bib10","unstructured":"National Institute of Neurological Disorders and Stroke. Peripheral neuropathy fact sheet. Updated 19 September 2012. http:\/\/www.ninds.nih.gov\/disorders\/peripheralneuropathy\/detail_peripheralneuropathy.htm [accessed 4 September 2013]."},{"key":"10.1016\/j.annepidem.2013.12.009_bib11","doi-asserted-by":"crossref","first-page":"337","DOI":"10.2147\/TCRM.S23889","article-title":"Pharmacovigilance analysis of adverse event reports for aliskiren hemifumarate, a first-in-class direct renin inhibitor","volume":"7","author":"Ali","year":"2011","journal-title":"Ther Clin Risk Manag"},{"issue":"12","key":"10.1016\/j.annepidem.2013.12.009_bib12","doi-asserted-by":"crossref","first-page":"1363","DOI":"10.1001\/archinte.165.12.1363","article-title":"Adverse drug event surveillance and drug withdrawals in the United States, 1969-2002: the importance of reporting suspected reactions","volume":"165","author":"Wysowski","year":"2005","journal-title":"Arch Intern Med"},{"issue":"5","key":"10.1016\/j.annepidem.2013.12.009_bib13","doi-asserted-by":"crossref","first-page":"407","DOI":"10.1002\/pds.615","article-title":"The role of databases in drug postmarketing surveillance","volume":"10","author":"Rodriguez","year":"2001","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.annepidem.2013.12.009_bib14","first-page":"1","article-title":"Assessing the association between omalizumab and arteriothrombotic events through spontaneous adverse event reporting","volume":"5","author":"Ali","year":"2012","journal-title":"J\u00a0Asthma Alelrgy"},{"issue":"6","key":"10.1016\/j.annepidem.2013.12.009_bib15","doi-asserted-by":"crossref","first-page":"1010","DOI":"10.1038\/clpt.2012.50","article-title":"Novel data-mining methodologies for adverse drug event discovery and analysis","volume":"91","author":"Harpaz","year":"2012","journal-title":"Clin Pharmacol Ther"},{"issue":"2","key":"10.1016\/j.annepidem.2013.12.009_bib16","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1038\/sj.clpt.6100258","article-title":"Novel statistical tools for monitoring the safety of marketed drugs","volume":"82","author":"Almenoff","year":"2007","journal-title":"Clin Pharmacol Ther"},{"issue":"7","key":"10.1016\/j.annepidem.2013.12.009_bib17","doi-asserted-by":"crossref","first-page":"796","DOI":"10.7150\/ijms.6048","article-title":"Data mining of the public version of the FDA Adverse Event Reporting System","volume":"10","author":"Sakaeda","year":"2013","journal-title":"Int J Med Sci"},{"issue":"3","key":"10.1016\/j.annepidem.2013.12.009_bib18","doi-asserted-by":"crossref","first-page":"177","DOI":"10.1080\/00031305.1999.10474456","article-title":"Bayesian data mining in large frequency tables, with an\u00a0application to the FDA Spontaneous Reporting System","volume":"53","author":"DuMouchel","year":"1999","journal-title":"Am Stat"},{"issue":"6","key":"10.1016\/j.annepidem.2013.12.009_bib19","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1038\/clpt.2013.24","article-title":"Performance of pharmacovigilance signal-detection algorithms for the\u00a0FDA adverse event reporting system","volume":"93","author":"Harpaz","year":"2013","journal-title":"Clin Pharmacol Ther"},{"issue":"4","key":"10.1016\/j.annepidem.2013.12.009_bib20","doi-asserted-by":"crossref","first-page":"972","DOI":"10.9734\/BJPR\/2013\/5633","article-title":"Pharmacovigilance analysis of adverse psychiatric events and suicidality reported for roflumilast, an add-on COPD therapy","volume":"3","author":"Ali","year":"2013","journal-title":"Br J Pharm Res"},{"issue":"7","key":"10.1016\/j.annepidem.2013.12.009_bib21","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.1007\/s00228-012-1219-4","article-title":"Adverse drug reactions: analysis of spontaneous reporting system in Europe in 2007-2009","volume":"68","author":"Srba","year":"2012","journal-title":"Eur J Clin Pharmacol"},{"issue":"12","key":"10.1016\/j.annepidem.2013.12.009_bib22","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.2165\/11584390-000000000-00000","article-title":"An experimental investigation of masking in the US FDA adverse event reporting system database","volume":"33","author":"Wang","year":"2010","journal-title":"Drug saf"},{"issue":"4","key":"10.1016\/j.annepidem.2013.12.009_bib23","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1136\/jnnp.62.4.310","article-title":"Epidemiology of peripheral neuropathy","volume":"62","author":"Martyn","year":"1997","journal-title":"J\u00a0Neurol Neurosurg Psychiatry"}],"container-title":["Annals of Epidemiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279713004754?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1047279713004754?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,20]],"date-time":"2025-10-20T02:14:32Z","timestamp":1760926472000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1047279713004754"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2014,4]]},"references-count":23,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2014,4]]}},"alternative-id":["S1047279713004754"],"URL":"https:\/\/doi.org\/10.1016\/j.annepidem.2013.12.009","relation":{},"ISSN":["1047-2797"],"issn-type":[{"value":"1047-2797","type":"print"}],"subject":[],"published":{"date-parts":[[2014,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Peripheral neuropathy and Guillain-Barr\u00e9 syndrome risks associated with exposure to systemic fluoroquinolones: a pharmacovigilance analysis","name":"articletitle","label":"Article Title"},{"value":"Annals of Epidemiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.annepidem.2013.12.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}